APR January/February 2022 - 69

« FORMULATION AND DEVELOPMENT
and innovation opportunities and not on burdensome laboratory
communication technology.
Moving forward, the participants plan to continue discussions in
other areas of interest and apply their learnings. Our first technology
development experience was a highly successful demonstration of
modern technologies and architecture. We determined that wearables
and other mobile devices are valuable tools for enhancing the
capabilities of a laboratory scientist if the right support is provided.
We also discovered that having a vendor-agnostic and integrated
approach for implementation will help us derive greater value. For
example, MS365 readily offered an integration of tools on the same
platform with familiar functionality, however this should be viewed as
a floor and not a ceiling, with more and deeper capabilities that could
be provided by vendors and partners with pharmaceutical domain
experience. Additionally, getting two complementary vendors to
integrate/interface together was also not as successful as we wished.
For this reason, our group has realized that only a long-term focused
industry engagement with vendors can enable the kind of solutions
the industry truly needs. Otherwise, vendors will continue to focus
on building monolithic solutions that fail to deliver on the promise
of these technologies. The benefit of a " consortia-based " approach is
that it allows the pharma industry to collaborate and achieve the level
of consensus necessary to alter this course and avoid our industry's
current environment where proprietary data, stored in closed systems
limits our ability to freely execute the scientific process. Changing this
course is perhaps the most impactful lever to pull in accelerating our
industry's ability to bring life changing medicines to patients.
Acknowledgements
This manuscript was developed with the support of the Enabling
Technologies Consortium (ETC) - www.etconsortium.org. ETC
is comprised of pharmaceutical and biotechnology companies
collaborating on issues related to pharmaceutical chemistry,
manufacturing, and control with the goal of identifying, evaluating,
developing, and improving scientific tools and techniques that support
the efficient development, and manufacturing of pharmaceuticals.
The authors would like to extend a special thanks to James Vergis
(ETC Secretariat and Director, Science & Technology at Faegre Drinker
Biddle & Reath LLP). The authors would like to also thank the following
individuals who made significant contributions to the ETC Project
Team and/or member company implementations:
AstraZeneca: Sophie Bailes
Biogen: Sean Johnston
BMS: Elizabeth Yuill and Xiaomei Zhou
Eli Lilly: Matthew Hyatt and Erik Butcher
Takeda: Michael Schwaerzler
References
Apprentice
Biogen
Bristol Myers Squibb
Eli Lilly & Co.
RealWear
Varya Virtual
1.
2.
www.apprentice.io
www.biogen.com
www.bms.com
www.lilly.com
www.realwear.com
www.varyavirtual.com
Smart Glasses and Augmented Reality in Pharma and Health Industry https://www.linkedin.
com/pulse/smart-glasses-augmented-reality-pharma-health-industry-jordi-boza
Pharma Manufacturers Using Smart Glasses for Virtual POV https://www.outsourcingpharma.com/Article/2015/10/29/Pharma-manufacturers-using-smart-glasses-forvirtual-POV
3.
A Quick guide for using Microsoft OneNote as an electronic laboratory notebook http://
journals.plos.org/ploscompbiol/article?id=10.1371/journal.pcbi.1006918
Author Biographies
Brian J. Good is a Senior Research Scientist within Bioproduct
Development at Eli Lilly & Company in Indianapolis, Indiana. He joined
Eli Lilly in 1995 and has held various positions in Chemical Process
Development, Analytical Chemistry, Information Delivery Solutions and
Bioproducts over that time. He is currently leading collaboration efforts
with academia, as well as industry consortia, in the areas of laboratory
automation, mobility and data analytics.
Geoff Kinnel is a Director at Bristol Myers Squibb and is the lead IT Business
Partner for the Drug Product Development group in New Jersey, US. He
received a MS in Engineering and Policy from Washington University in St.
Louis and an MS in Information Systems from Drexel University. He joined
Bristol Myers Squibb in 1997 as an information system analyst for the
Bioanalytical group. During his tenure at BMS, he has worked to enhance
and accelerate the pharmaceutical development process through the
introduction of innovative digital tools and systems.
Len Blackwell is an Associate Director at Biogen and leads the Analytical
Development - Strategic Analytics group whose mission is to bring
digitization and efficiency to the laboratories through automated
processes including robotics, data processing and data analytics.
His career path has transitioned from academia, biotechnology, and
biopharmaceuticals with a variety of companies and institutions. Len is
passionate about the realization of complete laboratory digitization in
the biopharmaceutical space. He received his Ph.D. in Biochemistry at
New York University.
Peter Tattersall, PhD, is a Director in Chemical and Process Development
within Product Development at Bristol-Myers Squibb Company in New
Jersey. He received his BSc. and Ph.D. from the University of Manchester,
UK. He previously worked in Analytical Development at AstraZeneca,
Wilmington. He joined Bristol Myers Squibb in 2003 where he is an project/
analytical team leader within Chemical and Process Development.
He also supervises a group of analytical chemists working on method
development, qualification, transfer and problem solving in support of
drug substance synthesis.
www.americanpharmaceuticalreview.com |
| 69
»
http://www.apprentice.io http://www.biogen.com http://www.bms.com http://www.lilly.com http://www.realwear.com http://www.varyavirtual.com https://www.linkedin.com/pulse/smart-glasses-augmented-reality-pharma-health-industry-jordi-boza https://www.outsourcingpharma. com/Article/2015/10/29/Pharma-manufacturers-using-smart-glasses-for-virtual-POV http://journals.plos.org/ploscompbiol/article?id=10.1371/journal.pcbi.1006918 http://www.etconsortium.org http://www.americanpharmaceuticalreview.com

APR January/February 2022

Table of Contents for the Digital Edition of APR January/February 2022

APR January/February 2022 - Cover1
APR January/February 2022 - Cover2
APR January/February 2022 - 1
APR January/February 2022 - 2
APR January/February 2022 - 3
APR January/February 2022 - 4
APR January/February 2022 - 5
APR January/February 2022 - 6
APR January/February 2022 - 7
APR January/February 2022 - 8
APR January/February 2022 - 9
APR January/February 2022 - 10
APR January/February 2022 - 11
APR January/February 2022 - 12
APR January/February 2022 - 13
APR January/February 2022 - 14
APR January/February 2022 - 15
APR January/February 2022 - 16
APR January/February 2022 - 17
APR January/February 2022 - 18
APR January/February 2022 - 19
APR January/February 2022 - 20
APR January/February 2022 - 21
APR January/February 2022 - 22
APR January/February 2022 - 23
APR January/February 2022 - 24
APR January/February 2022 - 25
APR January/February 2022 - 26
APR January/February 2022 - 27
APR January/February 2022 - 28
APR January/February 2022 - 29
APR January/February 2022 - 30
APR January/February 2022 - 31
APR January/February 2022 - 32
APR January/February 2022 - 33
APR January/February 2022 - 34
APR January/February 2022 - 35
APR January/February 2022 - 36
APR January/February 2022 - 37
APR January/February 2022 - 38
APR January/February 2022 - 39
APR January/February 2022 - 40
APR January/February 2022 - 41
APR January/February 2022 - 42
APR January/February 2022 - 43
APR January/February 2022 - 44
APR January/February 2022 - 45
APR January/February 2022 - 46
APR January/February 2022 - 47
APR January/February 2022 - 48
APR January/February 2022 - 49
APR January/February 2022 - 50
APR January/February 2022 - 51
APR January/February 2022 - 52
APR January/February 2022 - 53
APR January/February 2022 - 54
APR January/February 2022 - 55
APR January/February 2022 - 56
APR January/February 2022 - 57
APR January/February 2022 - 58
APR January/February 2022 - 59
APR January/February 2022 - 60
APR January/February 2022 - 61
APR January/February 2022 - 62
APR January/February 2022 - 63
APR January/February 2022 - 64
APR January/February 2022 - 65
APR January/February 2022 - 66
APR January/February 2022 - 67
APR January/February 2022 - 68
APR January/February 2022 - 69
APR January/February 2022 - 70
APR January/February 2022 - 71
APR January/February 2022 - 72
APR January/February 2022 - 73
APR January/February 2022 - 74
APR January/February 2022 - 75
APR January/February 2022 - 76
APR January/February 2022 - 77
APR January/February 2022 - 78
APR January/February 2022 - 79
APR January/February 2022 - 80
APR January/February 2022 - 81
APR January/February 2022 - 82
APR January/February 2022 - 83
APR January/February 2022 - 84
APR January/February 2022 - Cover3
APR January/February 2022 - Cover4
https://www.nxtbookmedia.com